title: Myocardial consequences of remifentanil in patients with coronary artery disease.
abstract: Remifentanil may be an alternative to conventional opioids for minimally invasive direct coronary artery bypass surgery because of its extremely short duration of action. The aim of this study was to investigate the effects of remifentanil on myocardial blood flow, metabolism and systemic haemodynamic variables in patients with coronary artery disease. After approval by the local ethics committee, 12 male patients were investigated before elective coronary artery bypass grafting. Systemic haemodynamic variables, myocardial blood flow and metabolism were measured when patients were awake and when they were anaesthetized with high-dose remifentanil (2.0 micrograms kg-1 min-1), or with remifentanil 0.5 microgram kg-1 min-1 combined with propofol (target-controlled infusion aiming at a plasma concentration of 2.0 micrograms ml-1). Myocardial blood flow was measured using a modified Kety-Schmidt technique. High-dose remifentanil anaesthesia significantly reduced cardiac index (CI) (-25%) as a consequence of a decrease in stroke volume index (SVI) (-14%) and heart rate (-13%). Mean arterial pressure (MAP) was 30% lower than that in the awake patient. Myocardial blood flow and myocardial oxygen uptake (MVO2) decreased by 30% and 42%, respectively. In contrast to high-dose remifentanil anaesthesia, systemic vascular resistance index (-14%) during remifentanil/propofol anaesthesia was significantly lower than that in the awake patient. Other haemodynamic variables, and myocardial blood flow and MVO2, did not significantly differ from the high-dose remifentanil period. In conclusion, high-dose remifentanil reduces SVI, heart rate, MAP, myocardial blood flow and MVO2 and its effects do not differ from those of remifentanil/propofol anaesthesia.
authors.affiliation: Department of Anaesthesiology, Emergency and Intensive Care Medicine, Georg August University of Göttingen, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Kazmaier
authors.forename: G G
authors.initials: GG
authors.lastname: Hanekop
authors.forename: W
authors.initials: W
authors.lastname: Buhre
authors.forename: A
authors.initials: A
authors.lastname: Weyland
authors.forename: T
authors.initials: T
authors.lastname: Busch
authors.forename: O C
authors.initials: OC
authors.lastname: Radke
authors.forename: R
authors.initials: R
authors.lastname: Zoelffel
authors.forename: H
authors.initials: H
authors.lastname: Sonntag
mesh_terms: D000368:Aged; D018686:Anesthetics, Intravenous / Q000008:administration & dosage / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D003326:Coronary Circulation / Q000187:drug effects*; D003327:Coronary Disease / Q000188:drug therapy*; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism; D009294:Narcotics / Q000008:administration & dosage / Q000494:pharmacology*; D010101:Oxygen Consumption / Q000187:drug effects; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology*; D015742:Propofol / Q000494:pharmacology*; D012039:Regional Blood Flow / Q000187:drug effects; D000077208:Remifentanil; D013318:Stroke Volume / Q000187:drug effects
chemical_list: D018686:Anesthetics, Intravenous; D009294:Narcotics; D010880:Piperidines; D000077208:Remifentanil; D015742:Propofol